Qu Biologics recruits Ms. Jennifer Archibald, Chief Financial Officer, and Mr. Alun Rees, VP, Manufacturing, to Leadership Team
08 nov. 2017 16h29 HE
|
Qu Biologics
VANCOUVER, British Columbia, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies...
Response to Novel Immune Therapy for Ulcerative Colitis Associated with Genetic and Immune Biomarkers
03 oct. 2017 12h16 HE
|
Qu Biologics
VANCOUVER, British Columbia , Oct. 03, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies...
Positive feedback from FDA reviewers in response to Pre-IND meeting package
14 août 2017 13h56 HE
|
Qu Biologics
VANCOUVER, British Columbia, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies...
Treatment with Qu Biologics’ Novel Immune Therapy for Ulcerative Colitis Results in High Clinical and Endoscopic Response Rates and Histological Improvement
02 août 2017 12h29 HE
|
Qu Biologics
VANCOUVER, British Columbia, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies...
Qu Biologics invited to present at US National Cancer Institute (NCI) Conference
12 juil. 2017 17h06 HE
|
Qu Biologics
VANCOUVER, British Columbia, July 12, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies...
Qu Biologics Publishes Proof-of-Principle Data for Promising New Treatment for Chronic Obstructive Pulmonary Disease (COPD)
23 mai 2017 15h30 HE
|
Qu Biologics
VANCOUVER, British Columbia, May 23, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) designed to “reboot” the...
Qu Biologics invited to present Research Data at International Scientific Meetings
03 mai 2017 12h47 HE
|
Qu Biologics
VANCOUVER, British Columbia, May 03, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies...
High Response and Remission Rates in Anti-TNFα Naïve Patients Treated with Qu Biologics’ Novel Immune Therapy for Crohn’s Disease
19 avr. 2017 15h26 HE
|
Qu Biologics
VANCOUVER, British Columbia, April 19, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies...
Innovation Grant Awarded for Qu Biologics Project with University of Ottawa Scientist
04 avr. 2017 15h15 HE
|
Qu Biologics
VANCOUVER, British Columbia, April 04, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies...
Qu Biologics Discovers That Immune Biomarkers May Predict Response to Novel Immune Therapy for Crohn’s Disease
22 mars 2017 18h22 HE
|
Qu Biologics
VANCOUVER, British Columbia, March 22, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies...